Clinical-stage gut microbiome therapeutics

Disease-Specific Microbiome Transplants.

Explore Pipelines Contact Our Team

What is a microbiome transplant?

A microbiome transplant introduces a healthy donor’s full microbial community to help restore ecosystem balance and function. LND’s approach is built around full-consortia products, disease-specific development, and clinical operational readiness.

Disease-specific development

Product strategy is aligned to indication biology (oncology, non-malignant, eating disorders).

High-grade storage

Health Canada approval for a 12-month shelf life with storage at -80°C.

Evidence-led iteration

Development informed by documented clinical outcomes and ongoing trial programs.

Services

Capsules and analytics

A portfolio across indications, plus analytics to support discovery and monitoring.

LND 101
Oncology

Capsule product focused on cancer patients.

Indications

Melanoma, lung, pancreatic, renal, breast

Stage

Phase 2b / Phase 1 (varies by indication)

LND 102
Non-malignant

Capsule product for a range of non-malignant conditions.

Focus

ALS, Parkinson’s, Fibromyalgia, MASLD

Stage

Phase 1 + Phase 2 planning

LND 103
Low-volume

Concentrated low-volume capsule product for eating disorders.

Indication

Anorexia Nervosa

Stage

Phase 1

Analysis
Multi-omics

End-to-end analytics to support trials and cohorts.

Includes

Metagenomics, functional/EC, metabolites, 16S rRNA

Outputs

Clinician-ready summaries & reproducible reporting

Explore pipelines